Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Ariflo Long-Term Efficacy Trials Needed For COPD Approval – FDA Cmte.

Executive Summary

GlaxoSmithKline's Ariflo needs long-term efficacy studies to confirm the PDE-4 inhibitor's maintenance of effect in chronic obstructive pulmonary disease, an FDA advisory committee agreed Sept. 5
Advertisement

Related Content

Nycomed Says Phase III Daxas COPD Data Show Drug Is Ready For A Second Shot
GSK Cidra Manufacturing FDA-483 Reports Cite Ariflo, 12 Other Products
GSK Cidra Manufacturing FDA-483 Reports Cite Ariflo, 12 Other Products
Ariflo COPD Long-Term Efficacy Studies Should Use Active Controls – Cmte.
Ariflo COPD Long-Term Efficacy Studies Should Use Active Controls – Cmte.
SB Paxil Exclusivity Defense: Synthon Files NDA For Paroxetine Mesylate
SB Paxil Exclusivity Defense: Synthon Files NDA For Paroxetine Mesylate
Advertisement
UsernamePublicRestriction

Register

PS042426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel